Dengue cases are rising globally, with Brazil and South America experiencing record highs.
year-on-year.
About Dengue
- Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes.
- About half of the world’s population is now at risk of dengue with an estimated 100–400 million infections occurring each year.
- Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
- While many dengue infections are asymptomatic or produce only mild illness, the virus can occasionally cause more severe cases, and even death.
- Prevention and control of dengue depend on vector control.
- There is no specific treatment for dengue/severe dengue.
- Early detection and access to proper medical care greatly lower fatality rates of severe dengue.
- Caused by: Dengue virus (Genus Flavivirus),
- Transmitted by: Several species of female mosquito within the genus Aedes principally Aedes aegypti.
- This mosquito also transmits chikungunya, yellow fever and Zika infection.
- 4 distinct serotypes (separate groups within a species of microorganisms that all share a similar characteristic) of the virus that cause dengue : DEN-1, DEN-2, DEN-3 and DEN-4.
Enroll now for UPSC Online Course
Global Burden of Dengue
- Dengue cases have surged globally, with over 6.5 million cases reported in 2023, surpassing the previous record of 5.2 million in 2019.
- In 2024 (till August) it reached an all time high with 12.06 Million reported cases and 6990 deaths.
- Many cases remain unreported or misdiagnosed, highlighting the true extent of the dengue burden.
Reason for Surge in Dengue Cases
- Urbanisation: Increased Population Density, Expansion of Cities & Human Movement
- Climate Change : Warmer temperatures and altered rainfall patterns.
- Increased frequency and intensity of extreme weather.
- Changing climate allows Aedes mosquitoes to expand their range.
Vaccines for Dengue
- Dengvaxia: It is a Live recombinant tetravalent vaccine recommended for ages 9–45 or 9–60 years, depending on the country.
- Safe for those with prior dengue infection and has shown around 80% efficacy.
- Qgenda: It is a Live-attenuated vaccine recommended for ages 6–16 in high transmission areas.
- Two-dose series to be administered three months apart.
- Till Now there is no Dengue vaccine available in India.
Check Out UPSC CSE Books From PW Store